Aging Target Discovery Gero's AI driven approach builds clinically relevant disease phenotypes from real world data and uses WES-enabled genetics to identify targets that span multiple indications, offering pharma partners a faster path to multi-indication programs and licenseable targets.

Real World Genetics The combination of real world phenotype data and whole-exome sequencing provides a rich data asset for target discovery and validation, enabling collaborations focused on de-risked early programs and data-driven decision making.

Preclinical AI Services As a preclinical stage company, Gero can partner to augment discovery pipelines with AI-driven target generation, phenotypic modeling, and genetic insights, accelerating early-stage programs and reducing upfront risk.

Cross Indication Targeting The platform's ability to identify shared biology across diseases enables cross-indication collaboration and portfolio level deals, appealing to pharma seeking broad-target strategies and efficiency.

Strategic Growth Fit Located in a biotech hub with a nimble team, Gero presents collaboration-ready partnerships for biotech and mid-sized pharma seeking AI-enabled discovery capabilities and access to novel targets with real-world and genetic context.